Status:
COMPLETED
Coronary Flow Reserve Changes After Semaglutide Treatment
Lead Sponsor:
Ekrem Bilal Karaayvaz
Collaborating Sponsors:
MEDICANA
Conditions:
The Study Focused on the Vascular Effects of Semaglutide in Both Diabetic and Non-diabetic Patients
Obesity &Amp; Overweight
Eligibility:
All Genders
28-65 years
Brief Summary
The goal of this observational study is to learn about the effects of semaglutide to coronary artery flow in diabetic and non-diabetic patients. The main question it aims to answer is: Does semagluti...
Eligibility Criteria
Inclusion
- Patients who were planned to start semaglutide.
Exclusion
- Ischemic heart disease
- Previous stent implantation or coronary bypass
- Heart failure
- Cardiomyopathies
- Inflammatory diseases
- Autoimmune rheumatic disease
- Chronic liver and renal insufficiency
Key Trial Info
Start Date :
January 7 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2025
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT07190144
Start Date
January 7 2025
End Date
August 1 2025
Last Update
September 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medicana International Istanbul Hospital
Istanbul, Turkey (Türkiye), 34520